First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial.
- DOI
- 10.1038/s41467-026-78190-9
- Published
- 2026 Oct 2
- Container
- Nature communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-026-78190-9,
title = {First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial.},
author = {Rosen EP and Bondoc S and Bailón L and Blay L and Caballero A and García-Guerrero MC and Puertas MC and Moraes-Cardoso I and Vazquez-Escobales A and Blanco J and Mothe B and Kashuba AD and Estes JD and Martinez-Picado J and Molto J and DUALITY study group},
year = {2026},
journal = {Nature communications},
doi = {10.1038/s41467-026-78190-9},
url = {https://doi.org/10.1038/s41467-026-78190-9}
}RIS
TY - JOUR TI - First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial. AU - Rosen EP AU - Bondoc S AU - Bailón L AU - Blay L AU - Caballero A AU - García-Guerrero MC AU - Puertas MC AU - Moraes-Cardoso I AU - Vazquez-Escobales A AU - Blanco J AU - Mothe B AU - Kashuba AD AU - Estes JD AU - Martinez-Picado J AU - Molto J AU - DUALITY study group PY - 2026 JO - Nature communications DO - 10.1038/s41467-026-78190-9 UR - https://doi.org/10.1038/s41467-026-78190-9 ER -
APA
EP, R., S, B., L, B., L, B., A, C., MC, G., MC, P., I, M., A, V., J, B., B, M., AD, K., JD, E., J, M., J, M., & group, D. S. (2026). First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial.. Nature communications. https://doi.org/10.1038/s41467-026-78190-9
Source records
- pubmed · retrieved 2026-11-10T14:17:40.687Z